Histiocyte‐rich, T‐cell‐rich B‐cell lymphoma: a distinct diffuse large B‐cell lymphoma subtype showing characteristic morphologic and immunophenotypic features

Achten, Ruth; Verhoef, Gregor; Vanuytsel, L.; Wolf‐Peeters, Chris De

doi:10.1046/j.1365-2559.2002.01291.x

Cited by 67 publications

(77 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD5 and CD138 are uniformly negative [13,15]. Bcl-6 and CD79a are expressed by the majority of tumors [13][14][15][16]29]. CD10 is positive in only a minority of cases [13][14][15][16].…”

Section: Pathologic Diagnosismentioning

confidence: 99%

“…2). The inflammatory response is further notable for the paucity of small B cells and other reactive cells, including neutrophils, eosinophils, and plasma cells [5,10,12,16,29]. Networks of CD21 + follicular dendritic cells are also absent [10,29].…”

Section: Pathologic Diagnosismentioning

confidence: 99%

“…As the name implies, a nodular pattern is www.TheOncologist.com characteristic of NLPHL, while T/HRBCL tends to be diffuse. That said, a vague nodularity has been reported in as many as three quarters of T/HRBCLs [29], so other diagnostic considerations are required. Unlike the HRS cells of cHL, the neoplastic L&H cells of NLPHL mark similarly to the malignant B cells of T/HRBCL.…”

Section: Distinguishing T/hrbcl From Other Entitiesmentioning

confidence: 99%

“…Rosettes of CD57 + T lymphocytes commonly surround the neoplastic L&H cells in NLPHL [15,20], though such rosettes are not seen within the reactive T-cell population of T/HRBCL [9,10,15]. Networks of CD21 + follicular dendritic cells are at least partially preserved in NLPHL but uniformly absent in T/HRBCL [9,10,20,29,32].…”

Section: Distinguishing T/hrbcl From Other Entitiesmentioning

confidence: 99%

See 3 more Smart Citations

T-Cell/Histiocyte-Rich B-Cell Lymphoma: Biology, Diagnosis, and Management

Abramson

2006

The Oncologist

View full text Add to dashboard Cite

show abstract

“…CD5 and CD138 are uniformly negative [13,15]. Bcl-6 and CD79a are expressed by the majority of tumors [13][14][15][16]29]. CD10 is positive in only a minority of cases [13][14][15][16].…”

Section: Pathologic Diagnosismentioning

confidence: 99%

Section: Pathologic Diagnosismentioning

confidence: 99%

Section: Distinguishing T/hrbcl From Other Entitiesmentioning

confidence: 99%

Section: Distinguishing T/hrbcl From Other Entitiesmentioning

confidence: 99%

See 2 more Smart Citations

T-Cell/Histiocyte-Rich B-Cell Lymphoma: Biology, Diagnosis, and Management

Abramson

2006

The Oncologist

View full text Add to dashboard Cite

show abstract

“…6 However, using a stricter definition requiring the presence of a prominent histiocytic component as a major feature and almost complete absence of small B lymphocytes, the unique character of this lymphoma has been demonstrated. 7,8 The precise relationship between THRLBCL and NLPHL remains unclear. 2,3,9 Indeed, the atypical B cells of NLPHL and THRLBCL share many characteristics, including expression of pan-B-cell markers, germinal center B-cell origin and common chromosomal imbalances.…”

Section: Introductionmentioning

confidence: 99%

T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response

Loo¹,

Tousseyn²,

Vanhentenrijk³

et al. 2009

Haematologica

View full text Add to dashboard Cite

The online version of this article has a Supplementary Appendix. BackgroundGene expression profiling has successfully identified the prognostic significance of the host response in lymphomas. The aggressive T-cell/histiocyte-rich large B-cell lymphoma and the indolent nodular lymphocyte-predominant Hodgkin's lymphoma are both characterized by a paucity of tumor cells embedded in an overwhelming background. The tumor cells of both lymphomas share several characteristics, while the cellular composition of their microenvironment is clearly different. Design and MethodsWe collected 33 cases of T-cell/histiocyte-rich large B-cell lymphoma and 56 cases of nodular lymphocyte-predominant Hodgkin's lymphoma and performed microarray gene expression profiling on ten cases of each lymphoma, to obtain a better understanding of the lymphoma host response. By quantitative reverse transcriptase polymerase chain reaction we verified that these 20 selected cases were representative of the entire population of T-cell/histiocyte-rich large B-cell and nodular lymphocyte-predominant Hodgkin's lymphomas. ResultsWe observed that the microenvironment in nodular lymphocyte-predominant Hodgkin's lymphoma is molecularly very similar to a lymph node characterized by follicular hyperplasia, while the microenvironment in T-cell/histiocyte-rich large B-cell lymphoma is clearly different. The T-cell/histiocyte-rich large B-cell lymphoma signature is hallmarked by up-regulation of CCL8, interferon-γ, indoleamine 2,3 dioxygenase, VSIG4 and Toll-like receptors. These features may be responsible for the recruitment and activation of T cells, macrophages and dendritic cells, characterizing the stromal component of this lymphoma, and may point towards innate immunity and a tumor tolerogenic immune response in T-cell/histiocyte-rich large B-cell lymphoma. ConclusionsThe gene expression profile of T-cell/histiocyte-rich large B-cell lymphoma, in comparison with that of nodular lymphocyte-predominant Hodgkin's lymphoma, shows features suggestive of a distinct tolerogenic host immune response that may play a key role in the aggressive behavior of this lymphoma, and that may serve as a potential target for future therapy.Key words: gene expression profiling, Hodgkin's lymphoma, THRLBCL.Citation: Van Loo P, Tousseyn T, Vanhentenrijk V, Dierickx D, Malecka A, Vanden Bempt I, Verhoef G, Delabie J, Marynen P, Matthys P, and De Wolf-Peeters C. T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response. Haematologica. 2010;95:440-448. doi:10.3324/haematol.2009 This is an open-access paper. T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response

show abstract

Diffuse Large B‐Cell Lymphoma

2011

The Diagnosis of Lymphoproliferative Diseases

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is a heterogenous class of aggressive lymphoma and is considered as the most common subtype of non-Hodgkin lymphomas (NHL). Several genetic anomalies such as point mutations, numerical alterations, and, more rarely, translocations and gene amplifications play a role in the pathogenesis of this class of B-cell lymphoma and have been related to specific histological and immunophenotypic subtypes. On the other hand, the treatment protocol in DLBCL did not witness significant changes during the last two decades. The widespread adoption of rituximab as an important adjuvant to standard chemotherapy protocol in CD20+ cases was a notable exception, which provided significant improvement in disease-free survival and overall survival, with limited toxicity. However, no less than 20% of patients diagnosed with DLBCL exhibit relapse after the initial response to R-CHOP regimen, while more than 15% of the patients exhibit primary refractory disease. This is the reason why a review of all the morphological, clinical, and therapeutic particularities of DLBCL is required.

show abstract

Histiocyte‐rich, T‐cell‐rich B‐cell lymphoma: a distinct diffuse large B‐cell lymphoma subtype showing characteristic morphologic and immunophenotypic features

Cited by 67 publications

References 38 publications

T-Cell/Histiocyte-Rich B-Cell Lymphoma: Biology, Diagnosis, and Management

T-Cell/Histiocyte-Rich B-Cell Lymphoma: Biology, Diagnosis, and Management

T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response

Diffuse Large B‐Cell Lymphoma

Contact Info

Product

Resources

About